Literature DB >> 6957263

Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

C M Camaggi, E Strocchi, V Tamassia, A Martoni, M Giovannini, G Lafelice, N Canova, D Marraro, A Martini, F Pannuti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6957263

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  29 in total

1.  Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.

Authors:  Lorraine D Ralph; Alison H Thomson; Nicola A Dobbs; Chris Twelves
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 2.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; A Tononi; M Guaraldi; M Strolin-Benedetti; C Efthymiopoulos; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; R Comparsi; F Testoni; B Angelelli; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; B Melotti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

9.  Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation.

Authors:  S Kobayashi; Y Narimatsu; K Ogawa; S Hashimoto; S Nakatsuka; H Miura; H Ohzono; W J Ka; K Ido; K Hiramatsu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.